Arrowhead Pharmaceuticals Files 8-K
Ticker: ARWR · Form: 8-K · Filed: Mar 19, 2024 · CIK: 879407
Sentiment: neutral
Topics: corporate-disclosure, financials, regulatory-filing
Related Tickers: ARWR
TL;DR
Arrowhead Pharma filed an 8-K on March 19th covering votes and financials.
AI Summary
Arrowhead Pharmaceuticals, Inc. filed an 8-K on March 19, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing date indicates the report was prepared as of March 14, 2024, with the earliest event reported on February 21, 2024. The company, previously known as Arrowhead Research Corp, is incorporated in Delaware and headquartered in Pasadena, California.
Why It Matters
This 8-K filing provides official updates on corporate actions and financial reporting for Arrowhead Pharmaceuticals, Inc., which is crucial for investors to stay informed about the company's governance and financial health.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain information that inherently increases risk.
Key Numbers
- 001-38042 — SEC File Number (Identifies the company's filing history with the SEC.)
- 46-0408024 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Arrowhead Pharmaceuticals, Inc. (company) — Registrant
- Arrowhead Research Corp (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Pasadena, CA (location) — Principal executive offices
- March 14, 2024 (date) — Date of earliest event reported
- March 19, 2024 (date) — Filing date
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of these matters are not provided in the excerpt.
What financial statements are included in this filing?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific financial statements are not detailed in the provided text.
When was the earliest event reported in this 8-K?
The earliest event reported was on February 21, 2024.
What was Arrowhead Pharmaceuticals, Inc. previously named?
The company was formerly known as Arrowhead Research Corp.
Where are Arrowhead Pharmaceuticals, Inc.'s principal executive offices located?
The principal executive offices are located at 177 E. Colorado Blvd, Suite 700, Pasadena, CA 91105.
Filing Stats: 640 words · 3 min read · ~2 pages · Grade level 13.3 · Accepted 2024-03-19 16:38:53
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ARWR The Nasdaq Global Select
Filing Documents
- arwr-20240314.htm (8-K) — 42KB
- 0001628280-24-011930.txt ( ) — 167KB
- arwr-20240314.xsd (EX-101.SCH) — 2KB
- arwr-20240314_lab.xml (EX-101.LAB) — 22KB
- arwr-20240314_pre.xml (EX-101.PRE) — 13KB
- arwr-20240314_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders The following proposals were submitted to the stockholders of Arrowhead Pharmaceuticals, Inc. (the "Company") at the 2024 Annual Meeting of Stockholders held on March 14, 2024: To elect seven directors to serve as members of the Company's Board of Directors until the next Annual Meeting or until their successors are elected; To approve, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers; and To ratify the selection of KPMG LLP as independent auditors of the Company for the fiscal year ended September 30, 2024. As of January 19, 2024, the record date for the Annual Meeting, the Company had 123,838,165 shares of its common stock outstanding and entitled to vote. At the Annual Meeting 106,986,420 shares were present in person or represented by proxy and entitled to vote. Based on the votes cast in person and by proxy, each proposal passed, including the election of each director. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below: Election of Directors NAME FOR AGAINST ABSTAIN NON VOTES Douglass Given 76,397,567 10,968,346 303,938 19,316,569 Michael S. Perry 82,446,900 4,911,855 311,096 19,316,569 Christopher Anzalone 84,313,696 2,976,660 379,495 19,316,569 Mauro Ferrari 81,342,884 6,020,799 306,168 19,316,569 Adeoye Olukoton 83,526,809 3,815,731 327,311 19,316,569 William Waddill 83,279,633 4,079,251 310,967 19,316,569 Victoria Vakiener 83,354,988 3,975,617 339,246 19,316,569 Advisory Vote to Approve Executive Compensation 82,576,047 FOR 4,950,419 AGAINST 143,385 ABSTAIN 19,316,569 NON VOTES Ratification of KPMG as Independent Auditors of the Company 104,057,945 FOR 2,562,563 AGAINST 365,912 ABSTAIN 0 NON VOTES
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: March 19, 2024 ARROWHEAD PHARMACEUTICALS, INC. By: /s/ Kenneth Myszkowski Kenneth Myszkowski Chief Financial Officer